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Protocol
AbstrACt
Introduction  Acute colorectal surgery forms a significant 
proportion of emergency admissions within the National 
Health Service. There is limited evidence to suggest 
minimally invasive surgery may be associated with 
improved clinical outcomes in this cohort of patients. 
Consequently, there is a need to assess the clinical 
effectiveness and cost-effectiveness of laparoscopic 
surgery in the acute colorectal setting. However,emergency 
colorectal surgical trials have previously been difficult 
to conduct due to issues surrounding recruitment and 
equipoise. The LaCeS (randomised controlled trial of 
Laparoscopic versus open Colorectal Surgery in the acute 
setting) feasibility trial will determine the feasibility of 
conducting a definitive, phase III trial of laparoscopic 
versus open acute colorectal resection.
Methods and analysis The LaCeS feasibility trial 
is a prospective, multicentre, single-blinded, parallel 
group, pragmatic randomised controlled feasibility trial. 
Patients will be randomised on a 1:1 basis to receive 
either laparoscopic or open surgery. The trial aims to 
recruit at least 66 patients from five acute general surgical 
units across the UK. Patients over the age of 18 with a 
diagnosis of acute colorectal pathology requiring resection 
on clinical and radiological/endoscopic investigations, with 
a National Confidential Enquiry into Patient Outcome and 
Death classification of urgent will be considered eligible 
for participation. The primary outcome is recruitment. 
Secondary outcomes include assessing the safety 
profile of laparoscopic surgery using intraoperative and 
postoperative complication rates, conversion rates and 
patient-safety indicators as surrogate markers. Clinical 
and patient-reported outcomes will also be reported. The 
trial will contain an embedded qualitative study to assess 
clinician and patient acceptability of trial processes.
Ethics and dissemination The LaCeS feasibility trial 
is approved by the Yorkshire and The Humber, Bradford 
Leeds Research Ethics Committee (REC reference: 15/ 
YH/0542). The results from the trial will be presented at 
national and international colorectal conferences and will 
be submitted for publication to peer-reviewed journals.
trial registration number ISRCTN15681041; Pre-results.
bACkground
Emergency general surgery is a huge clinical 
service, with approximately 1000 finished 
consultant episodes per 100 000 popula-
tion/year.1 2 Approximately 30% of emer-
gency admissions are secondary to colorectal 
pathology, namely, colorectal malignancy, 
inflammatory bowel disease and diverticular 
disease.3 4 More than 30 000 patients undergo 
an emergency laparotomy for a variety of 
intra-abdominal pathologies each year within 
the National Health Service (NHS) in England 
and Wales.5 In the UK, the National Emer-
gency Laparotomy Audit (NELA) reported 
outcomes on 23 198 patients, of which 37% 
underwent an emergency colorectal resec-
tion between December 2014 and November 
2015.6 The burden of emergency surgery 
is significant, with reports of 30-day post-
operative morbidity rates of 33%–71% and 
mortality rates of 14%–17%.
The NELA audit reports that the majority 
of emergency surgery is undertaken using 
an open approach, with approximately 
14% of all emergency abdominal opera-
tions commenced laparoscopically, of which 
strengths and limitations of this study
 ► This trial will assess the feasibility and acceptability 
of conducting a definitive, phase III randomised 
controlled trial of laparoscopic versus open 
emergency colorectal resection.
 ► The main challenges regarding recruitment, 
randomisation, equipoise, blinding and follow-up 
will be identified through the use of an embedded 
qualitative study.
 ► The main limitations of this trial are the lack of 
power to examine efficacy.
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only half are completed laparoscopically.6 The role of 
laparoscopic surgery in certain acute intra-abdominal 
pathologies (ie, acute appendicitis) has been well eluci-
dated in a number of randomised controlled trials, with 
reports of improved pain, shorter recovery and reduced 
length of hospital stay.7 8 Consequently, laparoscopic 
appendicectomy has become a well-established tech-
nique.9 In comparison, the current evidence of acute 
laparoscopic colorectal resection consists of a number 
of case series and cohort studies, which are limited 
by their retrospective nature, strict patient selection 
and small sample size.10 11 The evidence base for lapa-
roscopic surgery in the elective colorectal surgery is 
vast.12 13 However, applying this evidence to the acute 
setting is inappropriate due to the varying levels of 
sepsis, differing patient physiology and potentially more 
advanced disease states. The only way to integrate lapa-
roscopic surgery in the algorithm for acute colorectal 
pathology is to evaluate its safety and efficacy within the 
remit of a randomised controlled trial.
Surgical trials have been traditionally deemed to be 
difficult to undertake due to a range of practical and 
methodological challenges, including difficulties in 
recruitment, randomisation and lack of surgical equi-
poise.14 These issues are further amplified in the emer-
gency setting and therefore, it is important to conduct 
a feasibility trial to assess key trial processes to ensure 
successful delivery of a future definitive trial. This 
Figure 1 Trial schema.    
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protocol paper outlines the LaCeS (Laparoscopic versus 
open Colorectal Surgery in the acute setting feasibility 
trial). The trial aims to assess the feasibility, safety and 
acceptability of performing a large-scale definitive 
phase III randomised controlled trial comparing emer-
gency laparoscopic surgery with open surgery for acute 
colorectal pathology.
MEthods
design
The LaCeS feasibility trial is a prospective, multicentre, 
single-blinded, parallel group, pragmatic randomised 
controlled feasibility trial. At least 66 participants will be 
randomised on an equal basis to receive either laparo-
scopic surgery or open surgery across five UK centres.
Participants will be blinded to the randomisation allo-
cation until 7 days after surgery or the day of discharge, 
if earlier. Participants will be followed up at prespecified 
time intervals; 3 days, 7 days, 30 days, 3 months and 6 
months postoperatively. In addition, some patients will 
also be followed up 12 months postoperatively to assess 
the feasibility of collecting data out to this time point. 
The trial schema is outlined in figure 1.
PrIMAry outCoME
The primary outcome measure is recruitment. The trial 
aims to recruit at least 66 patients over a 15-month period 
across five UK centres, with a steady state of recruitment 
of five patients per month over the last 12 months of the 
trial period.
sECondAry outCoMEs
Key secondary outcomes include:
 ► To pilot the recruitment and randomisation processes 
and assess their acceptability to clinicians and patients 
within the emergency setting;
 ► To assess the safety profile of emergency laparoscopic 
surgery;
 ► To explore the potential optimal endpoints, either 
clinical or patient-reported, that could be used as a 
primary endpoint in a definitive phase III trial;
 ► To explore the practical application and success of 
blinding in the emergency setting;
 ► To test the feasibility and refine the strategy for 
collecting patient-reported quality-of-life data and 
resource-use data to inform a future economic 
evaluation.
study PoPulAtIon
The study population is those presenting to emer-
gency general surgery services with an acute colorectal 
pathology requiring urgent resectional surgery.
sEttIng
The study is being undertaken in five NHS hospitals with 
acute general surgery services, able to deliver emergency 
laparoscopic surgery. These hospitals are a mixture of 
teaching hospitals and district general hospitals with 
dedicated emergency surgery services.
ElIgIbIlIty
Patient inclusion criteria
 ► Aged ≥18 years.
 ► Diagnosis of acute colorectal pathology requiring 
resectional surgery (eg, acute diverticular disease, 
inflammatory bowel disease and colorectal cancer) 
confirmed radiologically and/or endoscopically.
 ► National Confidential Enquiry into Patient Outcome 
and Death classification of urgent.15
 – Defined as intervention for acute onset or clinical 
deterioration of potentially life-threatening condi-
tions, for those conditions that may threaten the 
survival of limb or organ. Normally within hours of 
decision to operate, subdivided into NELA catego-
ries of 2a (~2–6 hours) or 2b (~6–18 hours).
 ► Suitable candidate for surgery as judged by the oper-
ating surgeon.
 ► Suitable for laparoscopic and open surgery in the 
opinion of the operating surgeon.
 ► Suitable for laparoscopic and open surgery in the 
opinion of the anaesthetist.
 ► Informed written consent obtained.
 – In cases where the patient’s judgement is consid-
ered temporarily impaired in relation to the con-
dition causing his/her admission, for example, 
experiencing significant pain/distress/nausea or 
acute delirium secondary to sepsis, personal con-
sultee advice would be appropriate.
Patient exclusion criteria
 ► Haemodynamic instability requiring inotropic 
support.
 ► Acute non-colorectal pathology (eg, adhesional 
small bowel obstruction, appendicitis, peptic ulcer 
disease, etc).
 ► Hand-assisted laparoscopic surgery.
 ► Laparoscopy and peritoneal lavage alone for colorectal 
pathology.
 ► Insertion of an endoscopic stent followed by laparo-
scopic resection for colorectal pathology.
 ► Patients undergoing surgery for complications of 
elective colorectal operations.
 ► Pregnancy.
 ► Pre-existing cognitive impairment.
 ► Currently participating in another surgical trial.
site eligibility
The trial will be performed as a multicentre collaboration 
within the UK across approximately five sites. Participa-
tion of sites will be dependent on the following criteria:
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 ► Has dedicated emergency surgery services with appro-
priate provisions for emergency laparoscopic surgery;
 ► Has dedicated elective laparoscopic colorectal surgery 
services;
 ► Established previous involvement in clinical trials;
 ► Anticipating to recruit at least two to three patients 
per month.
surgeon eligibility
All participating consultant surgeons must have a subspe-
cialist interest in colorectal surgery and have performed 
a minimum of 50 laparoscopic colorectal resections and 
must perform at least 20 laparoscopic resections a year, 
with equivalent experience with open surgery (this can 
include procedures in both the emergency and elective 
setting).
rECruItMEnt And rAndoMIsAtIon ProCEss
All patients with suspected acute colorectal pathology will 
be assessed clinically, radiologically and/or endoscopi-
cally as per best clinical practice. Following confirmation 
of clinical and radiological/endoscopic diagnosis of an 
acute colorectal pathology requiring resection, patients 
will be approached for participation in the trial. Patients 
will only be approached for potential participation 
between the hours of 08:00 – 22:00.
Patients who are deemed to have temporary impair-
ment in their judgement (temporary lack of mental 
capacity), related to their condition (eg, experiencing 
significant pain/distress/nausea or acute delirium 
secondary to sepsis), can be entered into the trial if a 
personal consultee can be identified to advise about 
trial entry. A personal consultee will ideally be a family 
member or partner, and will be informed of all key trial 
processes. Once the patient regains capacity, written 
informed consent will be requested from the patient for 
ongoing participation within the trial. Given the emer-
gency nature of the trial, the time available to consider 
participation will be shorter than in the elective setting. 
Patients and personal consultees will be given as long as 
they need to consider participation in the trial. Ideally, 
this will be at least 2 hours.
Following appropriate surgical and anaesthetic assess-
ment and confirmation of the clinical diagnosis, patients 
will be randomised using a telephone or online randomi-
sation system, on a 1:1 basis to receive either laparoscopic 
or open surgery. Patients will be stratified to one of the 
two arms according to intended consultant surgeon in 
charge, age, body mass index, American Society of Anes-
thesiologists status, nature of underlying pathology and 
intended surgical procedure.
trIAl IntErvEntIons
surgery
For the purposes of this pragmatic trial, surgery, either 
open or laparoscopic, will be undertaken in accordance 
with local standard practice. Laparoscopic surgery 
includes the use of multiport and single-port incisions 
to establish pneumoperitoneum to enable surgical resec-
tion. Conversion to an open operation is defined as the 
use of a midline laparotomy wound for any part of the 
colorectal dissection. The use of a limited laparotomy 
wound to facilitate specimen extraction is permissible.
blinding
The process of blinding this patient population within 
the emergency setting will be piloted in this feasibility 
study. Participants will be blinded to the randomisation 
allocation for 7 days postoperatively or until the day of 
discharge, if earlier. Hypoallergenic dressings will be 
applied to mimic the distribution of the midline lapa-
rotomy wound and lateral port site wounds. To assess the 
success of the blinding protocol, the Bang Blinding Index 
will be used to calculate the proportion of non-blinded 
participants in the trial on day 7 postoperatively.16
outCoME AssEssMEnt
Primary outcome: recruitment
The primary outcome of this trial is recruitment. Data 
logs will be kept to assess:
 ► the number of patients screened for eligibility,
 ► the proportion of eligible patients consenting to 
participation and reasons for non-participation,
 ► the proportion of consenting patients undergoing 
randomisation and reasons for non-randomisation,
 ► the proportion of patients not receiving their 
randomised allocation and the reasons for this.
 ► The combination of quantitative and qualitative data 
regarding recruitment will enable us to understand 
the potential pool of eligible patients and reasons 
for non-participation and withdrawal throughout the 
recruitment process. This will enable us to further 
refine and develop our recruitment and randomisa-
tion processes for a definitive, phase III trial.
secondary outcomes
Safety
To assess the safety profile of acute laparoscopic surgery, 
the following outcomes will be assessed: conversion rates 
from laparoscopic surgery to open surgery, intraoperative 
and postoperative complication rates, the severity of post-
operative complications using the Clavien-Dindo grading 
system, the incidence of patient-safety indicators and 
30-day postoperative mortality rates.
Endpoint evaluation to identify the optimal primary endpoint(s) for 
a definitive phase III trial
A range of key outcomes will be collected, including:
 ► Clinical outcomes including length of high depend-
ency unit/intensive care unit stay, length of hospital 
stay, resumption of gastrointestinal function and 
oral intake, opioid analgesic use, reoperation rates 
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and readmission rates and details regarding histopa-
thology of the resected specimen;
 ► Patient-reported health-related quality-of-life data 
using the Gastrointestinal Quality of Life Index, the 
Short Form - 12 Health Survey, pain scores using the 
Brief Pain Inventory and the EuroQol-5D-5L;
 ► Resource use using dedicated patient-reported and 
site-completed Health Economics Questionnaires to 
measure primary and secondary healthcare service 
use;
 ► Patient and clinician acceptability of trial processes 
and procedures using in-depth qualitative interviews 
and a dedicated Patient Feedback Questionnaire.
These candidate endpoints will be explored quanti-
tatively and qualitatively to assess for completion rates, 
generate data to inform future power calculations and 
to identify which endpoint will be of most meaning and 
value to clinicians and patients as a primary endpoint for 
a definitive phase III trial. Candidate endpoints will be 
collected at various times during the course of the trial 
(table 1). Trial follow-up will cease when the last partici-
pant reaches 6 months postrandomisation.
QuAlItAtIvE substudy
Trial processes and their acceptability to clinicians and 
patients will be assessed using semistructured, in-depth 
qualitative interviews to optimise and design strategies for 
a definitive, phase III trial. Clinicians will be interviewed 
regarding overall trial processes, recruitment in the emer-
gency setting and potential primary endpoints for a future 
phase III trial. Patients will be interviewed to identify any 
issues with the randomisation process, preferential bias 
for one type of surgery, reasons for non-participation or 
withdrawal, refusal of treatment allocation and burden of 
participation.
sAMPlE sIzE CAlCulAtIon And stAtIstICAl AnAlysIs
The sample size has been chosen to allow the estimation 
of the parameters of interest to the necessary degree of 
precision, following the recommended rule-of-thumb 
of 30 participants per arm.17 The sample size has been 
calculated to account for a 10% attrition rate and aims to 
recruit at least 66 patients. This sample size will allow the 
estimation of morbidity and mortality rates with the lapa-
roscopic arm with 95% two-sided CIs of at most ±17%, 
allowing its safety profile to be demonstrated. Achieve-
ment of this recruitment target will also demonstrate feasi-
bility of a likely required recruitment rate for a successful, 
definitive, phase III trial.
The feasibility of recruitment and randomisation will 
be evaluated by summarising the screening, eligibility, 
consent and randomisation processes, including numbers 
of participants involved during each stage. Descriptive 
summaries of the participant recruitment pathways at 
the five recruiting centres will be presented. Reasons for 
non-participation in the study will be summarised. Partic-
ipant retention during follow-up, including number of 
participants completing/withdrawing from the study 
and reasons for withdrawal, will be presented by treat-
ment arm. Completion rates of data collected at the base-
line and follow-up visits will be summarised. The Bang 
Blinding Index at 7 days and the timings of non-blindings 
will be reported to inform the feasibility of blinding in 
a phase III trial. In addition, the relationship between 
Table 1 Schedule of events
Pretrial 
diagnostics Baseline Operative
3-Day 
postoperative 
review
7-Day 
postoperative
review
30-Day 
postoperative 
review
3, 6 and 
12* months 
postoperative 
assessment
Radiological/endoscopic 
diagnosis
✓
Medical assessment ✓ ✓ ✓ ✓ ✓
Participant completed 
questionnaires
✓ ✓ ✓ ✓ ✓
Operative details ✓
Complications ✓ ✓ ✓
Patient-safety indicators ✓
At discharge
✓†
Patient Feedback 
Questionnaire
✓
Blinding Questionnaire ✓
Resource usage ✓ ✓
At discharge
*Trial follow-up will cease when the last participant reaches 6 months postrandomisation.
†In-patients only
copyright.
 o
n
 15 August 2019 at Uni of Hull Consortia. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-018618 on 22 February 2018. Downloaded from 
6 Harji D, et al. BMJ Open 2018;8:e018618. doi:10.1136/bmjopen-2017-018618
Open Access 
patients, surgical team members and centres will be 
described to indicate the clustering structure of the feasi-
bility study to inform the design of a phase III trial. The 
safety profile of each treatment arm will be summarised 
through descriptive statistics. Mortality rates, intraoper-
ative and postoperative complication rates, conversion 
rates and patient-safety indicator rates will be reported 
with 95% CIs. All analyses will be conducted on an inten-
tion-to-treat basis. An analysis formally comparing the 
two treatment arms will not be performed due to the lack 
of power within this feasibility study, in addition to the 
purpose of this study.
EthICs
The trial will be performed in accordance with the 
principles of good clinical practice in clinical trials and 
the recommendations guiding physicians in biomed-
ical research involving human subjects adopted by the 
18th World Medical Assembly, Helsinki, Finland, 1964, 
amended at the 64th World Medical Association General 
Assembly, Fortaleza, Brazil, October 2013. Informed 
written consent will be obtained from the participants 
(or from personal consultees where appropriate) prior 
to randomisation into the study. The right of a patient 
to refuse participation without giving reasons will be 
respected. Participants remain free to withdraw at any 
time from the study without giving reasons and without 
prejudicing his/her further treatment.
dIssEMInAtIon
The results of this trial will be presented at relevant 
colorectal scientific meetings and will be published in 
peer-reviewed journals.
dIsCussIon
There is a lack of high-quality evidence on laparoscopic 
surgery for emergency colorectal resection. There are a 
number of well-documented challenges in undertaking 
emergency surgery trials, including issues with recruit-
ment, safety and surgical equipoise.18–20 The LaCeS feasi-
bility trial is a necessary requirement prior to embarking 
on a definitive, phase III trial. Conducting this feasibility 
trial with an embedded qualitative study will enable a 
greater understanding of trial processes and their accept-
ability, thus allowing refinement of methodology and 
infrastructure for a planned, robust, definitive trial.
This feasibility trial is the first of its kind to assess the 
role of resectional laparoscopic surgery in the acute 
colorectal setting. The trial aims to assess the role of 
blinding in the acute clinical scenario, the inclusion of 
patients with temporary loss of capacity and aims to deter-
mine the barriers to recruitment and participation within 
this framework. The evidence generated from this trial 
will not only help inform the design of a definitive, phase 
III trial but will also help inform future methodological 
work in recruiting and randomising patients in the 
emergency setting. Emergency surgery research, and in 
particular acute colorectal surgery research, has been 
limited to individual case series and cohort studies, due 
to perceived difficulties in recruitment, randomisation 
and retention of patients. The LaCeS feasibility trial will 
try to understand these issues and offer solutions to help 
overcome them through consultation with participating 
surgeons, patients, the trial management group and the 
trial steering committee. This will lead to the design of a 
pragmatic, phase III trial, which will reflect the opinions 
of all key stakeholders.
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